People
Nadim Ahmed, president of hematology at BMS, is leaving the company to, according to “pursue other opportunities.”
Despite a storied career in drug design that has spanned multiple decades, James Woody believes there is still a significant amount of work left to be accomplished with the development of tumor necrosis factor inhibitor biologics.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers and Shakers.
Billionaire entrepreneur Mark Cuban, best known as the owner of the Dallas Mavericks and an investor on the ABC business reality series “Shark Tank,” is diving into generic drugs with a new startup, dubbed Mark Cuban Cost Plus Drug Company.
Janet Woodcock, the longtime director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration is set to take over the top spot of the regulatory agency on an interim basis following the presidential inauguration of Joe Biden.
Like many biopharma companies, the global COVID-19 pandemic has caused delays while also offering opportunities for NeuroRx.
The COVID-19 pandemic that has upended life across the globe has also ignited a reawakening to the value of vaccines, and Hu believes the momentum will carry forward into the new year.
Slaoui will stay on as an adviser for one month. His resignation from the vaccine program was made at the request of the incoming Biden administration.
The U.S. Food and Drug Administration is experiencing abrupt and noticeable personnel changes as it continues to clash with the Health and Human Services, the department that oversees the agency and its operations.
BioSpace takes a look at some of the announcements that occurred Monday and will continue to update throughout the week.
PRESS RELEASES